286 related articles for article (PubMed ID: 30295400)
1. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.
Dunn KE; Weerts EM; Huhn AS; Schroeder JR; Tompkins DA; Bigelow GE; Strain EC
Addict Biol; 2020 Jan; 25(1):e12680. PubMed ID: 30295400
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
3. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
[TBL] [Abstract][Full Text] [Related]
4. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.
Tompkins DA; Smith MT; Mintzer MZ; Campbell CM; Strain EC
J Pharmacol Exp Ther; 2014 Feb; 348(2):217-26. PubMed ID: 24227768
[TBL] [Abstract][Full Text] [Related]
5. Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome.
Dunn K; Bergeria C; Huhn AS; Strain EC
Drug Alcohol Depend; 2020 Oct; 215():108212. PubMed ID: 32781310
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine for managing opioid withdrawal.
Gowing L; Ali R; White JM; Mbewe D
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
[TBL] [Abstract][Full Text] [Related]
9. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.
Ziedonis DM; Amass L; Steinberg M; Woody G; Krejci J; Annon JJ; Cohen AJ; Waite-O'Brien N; Stine SM; McCarty D; Reid MS; Brown LS; Maslansky R; Winhusen T; Babcock D; Brigham G; Muir J; Orr D; Buchan BJ; Horton T; Ling W
Drug Alcohol Depend; 2009 Jan; 99(1-3):28-36. PubMed ID: 18805656
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
[TBL] [Abstract][Full Text] [Related]
11. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
Kowalczyk WJ; Phillips KA; Jobes ML; Kennedy AP; Ghitza UE; Agage DA; Schmittner JP; Epstein DH; Preston KL
Am J Psychiatry; 2015 Aug; 172(8):760-7. PubMed ID: 25783757
[TBL] [Abstract][Full Text] [Related]
12. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
[TBL] [Abstract][Full Text] [Related]
13. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal.
Srivastava A; Kahan M; Njoroge I; Sommer LZ
Can Fam Physician; 2019 May; 65(5):e214-e220. PubMed ID: 31088887
[TBL] [Abstract][Full Text] [Related]
15. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
16. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
Huhn AS; Finan PH; Gamaldo CE; Hammond AS; Umbricht A; Bergeria CL; Strain EC; Dunn KE
Sci Transl Med; 2022 Jun; 14(650):eabn8238. PubMed ID: 35731889
[TBL] [Abstract][Full Text] [Related]
17. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
18. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
Lofwall MR; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
[TBL] [Abstract][Full Text] [Related]
19. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
Jain K; Jain R; Dhawan A
J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
